US Patent 7,449,464: Scope, Claims, and US Landscape
What does US 7,449,464 claim cover?
US 7,449,464 has two independent claim targets by structure and use:
- Claim 1 (compound scope): A compound of formula (III), including isomers, salts, or solvates of that compound.
- Claim 2 (composition scope): A pharmaceutical composition containing the compound of claim 1 plus one or more pharmaceutically acceptable carriers/excipients/buffers/adjuvants/stabilizers.
Practical reading for enforcement: the patent is written to be broad on (i) the chemical subject matter (formula coverage plus salt/isomer/solvate variants) and (ii) formulation use (any conventional formulation platform with acceptable excipients). The claims, as provided, do not add functional limitations (e.g., mechanism of action, target binding, therapeutic indication, route, dosage, or release profile). That reduces the claim’s dependence on specific biology and shifts infringement risk to whether an accused product contains or is made from a compound that reads on formula (III) and then whether it is sold in a composition that satisfies claim 2’s general carrier/excipient language.
What is the scope of Claim 1 (compound of formula III)?
Claim 1’s scope is driven by three layers of coverage:
-
Core chemical identity
- “A compound of formula (III)” means infringement depends on mapping the accused chemical to the atoms/connectivity and substituent pattern defined by the patent’s formula (III).
-
Variant coverage
- The claim explicitly includes isomers.
- It also includes salts.
- It also includes solvates.
Implication: Even if the marketed API is not the exact neutral parent structure, the patent text still reaches a range of product forms that stay within the same formula-defined scaffold.
- No stated performance constraints
- Based on the claim text you provided, Claim 1 does not require evidence of potency, binding affinity, pharmacokinetics, or a specific therapeutic effect. The claim is compositionally defined.
Claim 1 coverage map (as written)
| Element of claim |
Coverage trigger |
What is not required (from provided text) |
| Compound of formula (III) |
Chemical structure matches formula (III) |
Target, mechanism, assay data |
| Isomers |
Stereochemical or positional isomers within formula (III) |
Any specific stereopurity |
| Salts |
Salt forms of the formula (III) compound |
Specific counterion set |
| Solvates |
Solvate forms of the formula (III) compound |
Specific solvent identities |
What is the scope of Claim 2 (pharmaceutical composition)?
Claim 2 is a classic “formulation claim” with broad, conventional language:
- “A pharmaceutical composition comprising” the compound according to claim 1
- plus one or more pharmaceutically acceptable:
- carriers
- excipients
- buffers
- adjuvants
- stabilisers
Claim 2 coverage map (as written)
| Claim component |
Coverage trigger |
Scope breadth driver |
| Pharmaceutical composition |
A formulation sold or used as a pharmaceutical composition |
“One or more” excipient categories |
| Contains compound of claim 1 |
The API (or equivalent form) reads on formula (III) and its included variants |
Ties composition coverage to claim 1 |
| Acceptable carriers/excipients |
Any standard excipient/buffer/adjunct/stabilizer that is pharmaceutically acceptable |
Avoids formulation constraints |
Infringement pattern: if an accused product contains the formula (III) compound (or a salt/solvate/isomer that qualifies), Claim 2 is generally satisfied even if the formulation differs in excipient ratios or uses a standard buffer/stabilizer system.
Where does the landscape pressure concentrate?
With only the two claim texts provided, the patent landscape analysis concentrates on three US realities that dictate whether competitors face noninfringement or design-around risk:
-
Formula-anchored compound claims
- If competitors develop chemically distinct scaffolds (not covered by formula (III)), they likely avoid claim 1 regardless of formulation.
- If competitors use the same formula (III) compound or a covered variant, the formulation differences are unlikely to avoid Claim 2.
-
Salt/isomer/solvate breadth
- Competitors often attempt to avoid compound claims by selecting a different salt form or crystallization form. Because Claim 1 includes salts and solvates explicitly, those routes of design-around narrow.
-
Formulation breadth
- Claim 2 covers “one or more” carriers/excipients/buffers/adjuvants/stabilizers. This covers essentially any conventional pharmaceutical formulation once the API is within Claim 1.
What is the likely freedom-to-operate (FTO) shape in the US?
Given the claim language alone, the FTO decision tree is structural:
Scenario A: accused API maps to formula (III)
- High risk for Claim 1.
- High risk for Claim 2 if sold as a pharmaceutical composition.
Scenario B: accused API uses a different scaffold (not within formula (III))
- Low risk for Claim 1.
- Low risk for Claim 2 (because Claim 2 depends on Claim 1’s compound).
Scenario C: accused API is a salt/isomer/solvate of the same formula (III) compound
- High risk for Claim 1.
- High risk for Claim 2, regardless of the chosen salt/solvate/isomer form.
In other words: for this patent, the decisive factor is whether the accused chemistry reads on formula (III). Formulation variation typically does not move the infringement needle once formula coverage is met.
How does US 7,449,464 typically interact with other patent layers?
US pharmaceutical enforcement is often layered across:
- Primary compound patents (this one appears to be one)
- Process patents (synthetic routes)
- Polymorph/crystal form patents (solid-state forms)
- Method-of-treatment patents (indication or dosing regimen)
- Combination patents (fixed-dose combinations or add-on regimens)
With the claim language you supplied, US 7,449,464 is primarily a compound + composition foundation. That means other patents in the landscape (process, polymorph, methods) determine whether competitors can reach the market without triggering injunctions, but they do not change the structural risk posed by a formula-based Claim 1 and an excipient-agnostic Claim 2.
What should an investor or R&D team infer from the claim structure?
1) The patent reads on the API and on most normal product presentations
Claim 2’s excipient list is not limited to a particular dosage form. It is limited only by the existence of pharmaceutically acceptable carriers/excipients and by presence of the Claim 1 compound.
2) Design-around is chemically driven, not formulation driven
Because salt/isomer/solvate variants are included, design-around must likely come from changing:
- the core scaffold (avoid formula (III)), or
- the chemical species so it does not fall within the formula language.
3) Validity work will likely focus on chemistry scope and entitlement boundaries
For formula claims, validity challenges typically target whether the specification supports the breadth and whether prior art anticipates or renders obvious the claimed formula range. Without the specification text and the formula definition, those analyses cannot be grounded in specifics here.
Claim breadth summary
| Patent aspect |
Breadth level (based on provided claims) |
Enforcement leverage |
| Claim 1 chemical scope |
High (formula + isomers + salts + solvates) |
Strong if the API maps to formula (III) |
| Claim 2 formulation scope |
High (general pharmaceutically acceptable carriers/excipients) |
Strong if API maps to claim 1 |
| Functional limitations |
Low (none stated in provided text) |
Makes infringement less dependent on performance facts |
Key Takeaways
- US 7,449,464 is a formula-anchored compound patent (Claim 1) that also explicitly covers isomers, salts, and solvates.
- US 7,449,464 is a broad pharmaceutical composition patent (Claim 2) that covers compositions containing the Claim 1 compound with any pharmaceutically acceptable carriers/excipients/buffers/adjuvants/stabilizers.
- The decisive infringement question is whether a competitor’s API (or covered variant) falls within formula (III); formulation changes alone are unlikely to avoid Claim 2 if Claim 1 is met.
- For landscape and FTO, risk concentrates on chemical scope mapping to formula (III), not on excipient selection.
FAQs
1) Does Claim 2 require a specific indication or mechanism?
No. Based on the claim text provided, Claim 2 only requires a pharmaceutical composition containing the Claim 1 compound plus pharmaceutically acceptable excipients/carriers.
2) Can competitors avoid the patent by switching salt forms?
Claim 1 includes salts. Salt switching alone does not avoid Claim 1 if the salt is still a salt of a compound that fits formula (III).
3) Does Claim 1 cover stereoisomers?
Yes. Claim 1 expressly includes isomers.
4) Does formulation design (buffer/stabilizer choices) eliminate infringement risk?
Not under the provided claim language. Claim 2 is broad enough to cover compositions with “one or more” acceptable carriers/excipients/buffers/adjuvants/stabilizers.
5) What is the main design-around path for competitors?
Avoid the core chemistry so it does not fall within formula (III). Changing presentation into a different excipient system or dosage formulation is less likely to avoid Claim 2 if the API is within Claim 1.
[1] US Patent 7,449,464, Claims 1-2 (as provided by user).
